# A Study of ZL-1211 in Patients With Advanced Solid Tumor

> **NCT05065710** · PHASE1 · COMPLETED · sponsor: **Zai Biopharmaceutical (Suzhou) Co., Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** ZL-1211

## Key facts

- **NCT ID:** NCT05065710
- **Lead sponsor:** Zai Biopharmaceutical (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-19
- **Primary completion:** 2024-03-09
- **Final completion:** 2024-04-09
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05065710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05065710, "A Study of ZL-1211 in Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05065710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*